Skip to content
OpenCapital
Get started

ADMA Biologics ADMA Interest Paid, Excluding Capitalized Interest, Operating Activity

Interest Paid, Excluding Capitalized Interest, Operating Activity at other companies

Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
——
Charles River Laboratories logo
Charles River LaboratoriesCRL
——

Other financials

Income statement

See full
Revenue$114.5M-0.3%
Gross profit$80.8M+32.2%
Operating income$58.3M+67.1%
Net income$45.3M+68.5%
EPS (diluted)$0.19+72.7%

Balance sheet

See full
Cash & equivalents$138.2M+92.9%
Total debt$204.4M+2,055%
Total equity$390.3M+4.5%
Total assets$665.2M+30.3%

Cash flow

See full
Operating cash flow$58.2M+396%
CapEx$2.5M-45.9%
Free cash flow$55.7M+329%

Valuation

See full
Market cap$2.02B-54.5%

Profitability

See full
Gross margin61.3%+8.7pp
Operating margin42.1%+9.0pp
Net margin32.4%-12.6pp
FCF margin21.2%+1.4pp

Returns & leverage

See full
Return on equity43.3%-35.2pp
Debt / equity0.5×+0.5×
Current ratio7×+0.4×

Where this comes from

Reported directly by ADMA Biologics in its filing.

Tagged under the XBRL concept us-gaap:InterestPaidNet.

The official record: ADMA Biologics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about ADMA Biologics's interest paid, excluding capitalized interest, operating activity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ADMA Biologics's interest paid, excluding capitalized interest, operating activity?
ADMA Biologics (ADMA) reported interest paid, excluding capitalized interest, operating activity of $1.33M in Q1 2026.
How has ADMA Biologics's interest paid, excluding capitalized interest, operating activity changed year-over-year?
ADMA Biologics's interest paid, excluding capitalized interest, operating activity decreased by 51.8% year-over-year, from $2.75M to $1.33M.
What is the long-term trend for ADMA Biologics's interest paid, excluding capitalized interest, operating activity?
Over 2 years (2023 to 2025), ADMA Biologics's interest paid, excluding capitalized interest, operating activity has grown at a -29.1% compound annual growth rate (CAGR), from $18.05M to $9.08M.